Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Group A streptococcus (GAS) is a bacterial pathogen responsible for a wide array of disease pathologies in humans. GAS surface M protein plays multiple key roles in pathogenesis, and serves as a target for typing and vaccine development. In this review, we have compiled GAS epidemiological studies from several countries around the world to highlight the consequences on the theoretical efficacy of two different M protein-based vaccine strategies.
Smeesters
Pierre R
PR
Bacterial Pathogenesis Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia. psmeeste@ulb.ac.be
McMillan
David J
DJ
Sriprakash
Kadaba S
KS
Georgousakis
Melina M
MM
D000942:Antigens, Bacterial / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D015195:Drug Design; D014644:Genetic Variation; D014943:Global Health; D006801:Humans; D017720:Molecular Epidemiology; D012720:Severity of Illness Index; D013290:Streptococcal Infections / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000276:immunology; D013297:Streptococcus pyogenes / Q000235:genetics* / Q000276:immunology; D016896:Treatment Outcome
D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002352:Carrier Proteins; D022541:Streptococcal Vaccines; C014689:streptococcal M protein